Investor Presentaiton
Immunology
LPA₁
Sotyktu
CD19 NEX T
SLE Phase 2 results across endpoints provide rationale for
Phase 3
100
SRI(4) response rates at week 481
A 22.7
(95% CI, 7.4-36.6)
OR: 2.6 (95% CI, 1.4-4.8)
Achievement of Lupus Low Disease Activity (LLDAS) at week 481
100
80
60
Response rate, %
50
60
40
40
20
20
P<0.001
57.1
47.3
47.2
34.4
0
n = 90
n = 91
n = 93
n = 89
Placebo
deucravacitinib 3 mg BID
80
60
60
60
Δ 22.9
(95% CI, 9.6-35.3)
OR: 4.0 (95% CI, 1.9-8.5)
P<0.001
Response rate, %
40
20
20
36.3
25.8
23.7
13.3
n = 90
n = 91
n = 93
n = 89
0
deucravacitinib 6 mg BID
deucravacitinib 12 mg QD
Met the primary endpoint, and all secondary endpoints achieved or meaningfully improved at week 48
with a well tolerated safety profile consistent with earlier trials
1. Morand E, et al. Arthritis & Rheumatology. 2023 Feb;75(2):242-252.; Multiplicity-adjusted secondary end point; Primary endpoint was met: percentage of patients
Ill Bristol Myers Squibb achieving SRI (4) at week 32 (P<0.001)
Not for Product Promotional Use
62View entire presentation